Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881622 | 0.86 | KDM4E (0.41) | KDM4EGSK3BSMN1; SMN2MAPTHTT | |
| SCHEMBL10034802 | 0.79 | KDM4E (0.54) | KDM4EALOX5SMN1; SMN2GAAMAPT | |
| SCHEMBL881345 | 0.72 | KDM4E (0.50) | KDM4EGSK3BSMN1; SMN2MAPTHTT | |
| SCHEMBL1481530 | 0.70 | PTPN1 (0.41) | KDM4EGSK3BSMN1; SMN2GAALMNA | |
| SCHEMBL23112345 | 0.69 | CTNNB1 (0.42) | KDM4EHTTALDH1A1HPGDHSD17B10 | |
| SCHEMBL639330 | 0.68 | CTNNB1 (0.59) | KDM4EMAPT | |
| SCHEMBL627847 | 0.67 | ATM (0.70) | KDM4ESMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL10067201 | 0.67 | ALOX5 (0.37) | KDM4EALOX5SMN1; SMN2GAAMAPT | |
| SCHEMBL881625 | 0.66 | KDM4E (0.61) | KDM4ESMN1; SMN2GAAMAPTLMNA | |
| SCHEMBL12565682 | 0.66 | GSK3B (0.45) | KDM4EGSK3BLMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822520-B2 | Substituted bicyclic HCV inhibitors | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822520-B2 | Substituted bicyclic HCV inhibitors | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2012040389-A2 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010111673-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | HAVCR2, LIPC, EIF2AK2 | KDM4E 3798/4885ALOX5 4104/4885CD274 3328/4885 |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | HAVCR2, LIPC, EIF2AK2 | KDM4E 3798/4885ALOX5 4104/4885CD274 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.